Notice Number: NOT-HL-16-477

Key Dates
Release Date: December 5, 2016

Estimated Publication Date of Announcement: March 2017
First Estimated Application Due Date: June 2017
Earliest Estimated Award Date: February 2018
Earliest Estimated Start Date: April 2018

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The National Heart, Lung, and Blood Institute (NHLBI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) which will support studies to evaluate the effect of sex hormones and sex hormone-based therapies on thrombus formation in pre-menopausal women. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in March 2017 with an expected application due date in June 2017.

This FOA will utilize the R61/R33 activity code. Details of the planned FOA are provided below.

Research Initiative Details

The intended FOA will seek applications that aim to identify and evaluate the basic molecular and cellular mechanisms to explore normal hormonal regulation of cellular functions as well as perturbations induced by elevated levels of endogenous sex hormones or during exogenous sex-hormone therapies.

The intended FOA will utilize a biphasic funding mechanism (R61/R33) to support two major consecutive research needs. The R61 Phase (up to two years) will support innovative applications that propose exploratory and developmental research either developing or optimizing a model system of hormone-induced thrombosis in pre-menopausal women. The R33 Phase (up to three years) will expand upon the developmental/exploratory work of the R61 Phase. The ultimate goal is to identify and evaluate the basic cellular, molecular and physiological mechanisms that underlie sex hormone or sex hormone therapy induced thrombosis. The FOA will seek applications that propose research plans for both the R61 and R33 phases and also include milestones to be achieved during the R61 Phase to qualify for the transition to the R33 Phase.

APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.

Inquiries

Please direct all inquiries to:

Nahed El Kassar, MD, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0050
Email: nahed.elkassar@nih.gov